1. What Is the Protein A Resin Market?
The Protein A Resin Market encompasses affinity chromatography resin media bearing recombinant Protein A ligands derived from Staphylococcus aureus cell wall protein. These selectively bind the Fc region of IgG antibodies for capture and purification of monoclonal antibody therapeutics from mammalian cell culture harvest. High selectivity, capacity, and binding strength enable single-step mAb capture at greater than 95 percent purity from complex cell culture fluid. The market includes a dominant commercial mAb capture resin, Protein A resin for biopharmaceutical process chromatography, and Protein A resin for single-use and stainless steel mAb purification. It also includes alkaline-stable Protein A resin for mAb capture and advanced Protein A resins with improved dynamic binding capacity for intensified bioprocessing at higher cell culture titers. These resins are consumed by biopharmaceutical manufacturers purifying commercial-scale monoclonal antibody therapeutics including adalimumab, pembrolizumab, and dupilumab at multi-tonne annual production batches requiring Protein A capture chromatography at commercial GMP manufacturing scale. They are also consumed by contract development and manufacturing organisations providing process development and GMP manufacturing services. Market scope covers recombinant Protein A ligand affinity chromatography resin media for mAb and Fc-fusion protein capture and purification. It excludes Protein G and Protein L resin with different immunoglobulin binding specificity and ion exchange and mixed-mode polishing resins for antibody purification without Protein A affinity ligand. Protein A ELISA detection reagents without chromatography resin form are also excluded.
2. Protein A Resin Market Size & Forecast
3. Emerging Technologies
- Protein A resin with tiered pricing for biosimilar market access is advancing standardised lower-cost Protein A resin product lines providing GMP-quality Protein A capture resin at 30 to 50 percent lower cost per litre. Growing biosimilar manufacturer interest in Protein A resin cost reduction as a primary bioprocessing cost driver is motivating lower-cost GMP-grade Protein A resin product line development.
- Continuous Protein A chromatography for mAb productivity improvement is advancing periodic counter-current PCC three to four column Protein A capture systems enabling productivity per litre of resin above batch single-column operation through continuous load. Growing biopharmaceutical manufacturer interest in Protein A capture productivity improvement through continuous chromatography is motivating multi-column PCC Protein A system development.
- Single-use Protein A capture for flexible GMP biomanufacturing is advancing prepacked disposable Protein A chromatography column cartridge systems enabling single-use mAb capture without column packing and cleaning between batches for flexible multi-product GMP manufacturing. Growing CDMO and multi-product biopharmaceutical facility interest in single-use Protein A column flexibility and cleaning elimination is motivating prepacked disposable Protein A column product development.
- Alkaline cleaning stability improvement for Protein A resin lifespan extension is advancing protein engineering of recombinant Protein A ligands stabilising asparagine deamidation and beta-elimination sites degraded by 0_5 to 1_0 molar NaOH CIP. Growing biopharmaceutical manufacturer interest in Protein A resin life cycle extension from improved alkaline stability is motivating protein engineering of Protein A ligand CIP stability.
Such innovations are driving change across adjacent industries too. Discover more in our Protein A Chromatography Market.
4. Key Market Opportunity
A major opportunity in the Protein A Resin Market is the expansion of high-capacity Protein A resin adoption at new biopharmaceutical manufacturing facility design as process intensification architectures using periodic counter-current PCC capture require high-DBC resin enabling smaller facility footprint at. A significant proportion of planned new biopharmaceutical mAb manufacturing facilities evaluate process intensification PCC capture architectures requiring high-DBC Protein A resin above 70 grammes per litre as the enabling material for column count and facility size reduction compared with single-column batch capture. High-DBC Protein A resin enabling intensified PCC mAb capture reduces facility column count, resin volume, and buffer consumption per gram of mAb produced at equivalent annual throughput to conventional batch chromatography. Protein A resin producers that develop validated high-DBC resin for PCC intensified platforms, build regulatory filing support for CMC substitution, and provide PCC process development services are positioned to capture growing intensified mAb manufacture resin demand.
5. Top Companies in the Protein A Resin Market
The following organisations hold leading positions in the Protein A Resin Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Cytiva (MabSelect SuRe)
- Merck KGaA (ProSep/KanCap)
- Repligen (SSKL)
- JSR Life Sciences (Amsphere A3)
- Tosoh Bioscience (AF-rProtein A)
- Bio-Rad Laboratories
- Navigo Proteins
- Purolite (Ecolab)
- Thermo Fisher
- Sartorius
6. Market Segmentation
The Protein A Resin Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Resin Generation | Native Protein A Recombinant Protein A Alkali-Stable Engineered Protein A High-Capacity Protein A |
| By Capacity | Standard 25-35 g/L High Cap 50-70 g/L Ultra High 80+ |
| By Compatibility | Alkali Stable CIP Tolerant Single Use Reusable 200+ |
| By End User | Biopharmaceutical Manufacturers Contract Manufacturers Biosimilar Manufacturers Academic and Research Labs |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Protein A Resin Market trajectory over the forecast period:
Cytiva MabSelect SuRe Maintains Global Market Leadership in mAb Capture Protein A Resin.Biopharmaceutical commercial mAb manufacturing operations purifying blockbuster antibody therapeutics at tonne-per-year production rates specify Cytiva MabSelect SuRe PCC Protein A resin validated for periodic counter-current capture with 0_5 molar sodium hydroxide CIP. High dynamic binding capacity above 55 grammes IgG per litre, and regulatory filing history spanning over 50 approved commercial mAb processes establishing MabSelect SuRe as the dominant commercial Protein A capture resin. Cytiva continued MabSelect SuRe production and delivery to commercial biopharmaceutical mAb manufacturing customers in 2024, with consistent demand from approved mAb manufacturing processes locked to MabSelect SuRe specification through regulatory CMC filing commitments.
Biosimilar Antibody Manufacturing Growth Is Creating New Protein A Resin Demand Outside Innovator Brands.Biosimilar mAb manufacturers in South Korea, India, and China producing approved biosimilar adalimumab, bevacizumab, and trastuzumab at growing commercial production scale adopt Protein A capture resin for GMP biosimilar purification from cell culture harvest. Biosimilar manufacturer competitive cost pressure motivating evaluation of alternative Protein A resin suppliers offering lower cost per gram of antibody purified versus Cytiva MabSelect SuRe at equivalent binding capacity. Repligen, JSR, and Tosoh continued Protein A resin marketing to biosimilar mAb manufacturers in South Korea, India, and China in 2024. Growing biosimilar market entry driving Protein A resin demand outside the innovator locked-specification biopharmaceutical segment at price-competitive alternative resin supplier evaluation.
High-Dynamic-Binding-Capacity Protein A Resin Is Enabling Intensified Bioprocess Platform Design.Biopharmaceutical process intensification programmes targeting smaller footprint. Higher productivity mAb manufacturing use high-DBC Protein A resin with greater than 70 grammes IgG per litre binding capacity for periodic counter-current multi-column chromatography enabling equivalent mAb capture throughput. These practices include from smaller resin volume and column diameter than single-column batch Protein A chromatography at conventional 35 grammes per litre DBC. Cytiva and JSR Life Sciences continued high-capacity Protein A resin development and delivery to intensified bioprocess platform development customers in 2024, growing biopharmaceutical process intensification adoption at new facility design stage driving high-DBC resin specification.
For related market intelligence, see the Affinity Resin Market.
8. Segmental Analysis
By resin brand, MabSelect SuRe dominated the Protein A Resin Market in 2025, driven by Cytiva's regulatory filing lock-in at the majority of commercial mAb manufacturing processes generating the highest single-brand Protein A resin revenue. Cytiva MabSelect SuRe commercial mAb capture resin consumption at approved innovator mAb manufacturing operations locked to MabSelect SuRe CMC specification continues generating the highest Protein A resin market revenue as the dominant single brand at. Alternative resins including JSR Amsphere and Repligen SSKL are the fastest-growing, driven by biosimilar manufacturer cost pressure and CDMO multi-resin qualification motivating alternative Protein A resin adoption outside innovator-locked commercial processes. Biosimilar manufacturer and CDMO alternative Protein A resin adoption from JSR, Repligen, and Tosoh driven by cost and supply diversity motivations is generating alternative resin market share growth above MabSelect SuRe volume growth rates.
By capacity, standard 25-35 gramme per litre DBC resins dominated the Protein A Resin Market in 2025, driven by the large installed commercial manufacturing base operating validated standard DBC processes locked in CMC regulatory filings. Commercial mAb manufacturing operations with CMC-locked standard DBC Protein A chromatography continue generating the highest market demand as existing commercial process validation is the primary constraint maintaining standard DBC resin dominance by resin volume consumed. High-capacity 50-70 g/L DBC resins are the fastest-growing, driven by new facility design adoption of high-DBC resin for process intensification PCC chromatography architectures at above-market growth rates. New biopharmaceutical facility process intensification programme adoption of high-DBC PCC Protein A capture and CDMO platform evaluation of high-DBC resin for productivity improvement are generating high-capacity resin market growth above standard DBC resin rates.
9. Regional Analysis
Regional demand patterns across the Protein A Resin Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Protein A Resin Market in 2025, with a market share of 45.0%. The region's leadership reflects the largest single concentration of commercial mAb manufacturing operations at North American biopharmaceutical sites including Abbvie, Regeneron, Bristol Myers Squibb, and Pfizer biomanufacturing facilities generating the highest aggregate Protein A resin consumption, and Repligen North American operations as a key alternative Protein A resin supplier. Large-scale commercial mAb manufacturing at North American biopharmaceutical facilities consuming Cytiva MabSelect SuRe creates the highest North American Protein A resin demand as the largest mAb commercial manufacturing geography. Growing North American biosimilar manufacturer Protein A resin demand and Repligen alternative resin programme create consistent North American sector leadership.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 13.00% during the forecast period. Growing South Korean and Chinese biosimilar mAb manufacturing capacity requiring Protein A capture resin, growing Indian biopharmaceutical CDMO mAb manufacturing services, and growing Chinese innovator biopharmaceutical mAb manufacturing pipeline are driving above-average growth. South Korean biosimilar mAb manufacturers Samsung Bioepis and Celltrion and growing Chinese biosimilar and innovator mAb manufacturing capacity create consistent Asia Pacific Protein A resin demand growth. Growing Indian CDMO mAb manufacturing services adoption and expanding Asia Pacific biosimilar pipeline advancement to commercial manufacturing create consistent Asia Pacific Protein A resin market demand growth above European baseline rates.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Protein A Resin Market was valued at USD 863.41 Mn in 2025 and is projected to reach USD 2,120.67 Mn by 2034, growing at a CAGR of 10.50% over the 2026–2034 forecast period.
The Protein A Resin Market is projected to grow at a CAGR of 10.50% from 2026 to 2034.
North America dominated the Protein A Resin Market in 2025, with a market share of 45.0%.
The leading companies in the Protein A Resin Market include Cytiva (MabSelect SuRe), Merck KGaA (ProSep/KanCap), Repligen (SSKL), JSR Life Sciences (Amsphere A3), Tosoh Bioscience (AF-rProtein A), Bio-Rad Laboratories, Navigo Proteins, Purolite (Ecolab), Thermo Fisher, Sartorius.
Cytiva mabselect sure maintains global market leadership in mab capture protein a resin.
By resin brand, MabSelect SuRe dominated the Protein A Resin Market in 2025, driven by Cytiva's regulatory filing lock-in at the majority of commercial mAb manufacturing processes generating the highest single-brand Protein A resin revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.